Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Anja von Heydebreck"'
Autor:
Ulrich Keilholz, Janice M. Mehnert, Sebastian Bauer, Hugues Bourgeois, Manish R. Patel, Donald Gravenor, John J. Nemunaitis, Matthew H. Taylor, Lucjan Wyrwicz, Keun-Wook Lee, Vijay Kasturi, Kevin Chin, Anja von Heydebreck, James L. Gulley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background We report phase 1b data from patients enrolled in the JAVELIN Solid Tumor clinical trial (NCT01772004) with unresectable stage IIIC or IV melanoma that had progressed after ≥1 line of therapy for metastatic disease. Patients and
Externí odkaz:
https://doaj.org/article/f697bdfa85314d5baa3633869a3141f3
Autor:
Christophe Le Tourneau, Christopher Hoimes, Corrine Zarwan, Deborah J. Wong, Sebastian Bauer, Rainer Claus, Martin Wermke, Subramanian Hariharan, Anja von Heydebreck, Vijay Kasturi, Vikram Chand, James L. Gulley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-9 (2018)
Abstract Background We assessed the efficacy and safety of avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with previously treated metastatic adrenocortical carcinoma (mACC). Methods In this phase 1b expansion cohort, patien
Externí odkaz:
https://doaj.org/article/a4ceab0673434817a6195d71e7e0f67e
Autor:
Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Céleste Lebbé, Michele Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Meliessa Hennessy, Paul Nghiem
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-7 (2018)
Abstract Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-
Externí odkaz:
https://doaj.org/article/8702b9ace3ed4ea195be94aaa6b2d065
Autor:
Sandra D'Angelo, Celeste Lebbé, Laurent Mortier, Andrew Brohl, Nicola Fazio, Jean-jaques Grob, Natalie Prinzi, Glenn Hanna, Jessica Hassel, Felix Kiecker, Anja von Heydebreck, Gülseren Güzel, Paul Nghiem
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Paul Nghiem, Patrick Terheyden, Anja von Heydebreck, Isaac Brownell, Howard L. Kaufman, Meliessa Hennessy, Omid Hamid, Karl D. Lewis, Céleste Lebbé, Shailender Bhatia, Jeffery S. Russell, Michele Milella, Jochen H. Lorch, Sandra P. D'Angelo, Kent C. Shih
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-7 (2018)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, si
Autor:
Borys Hrinczenko, Kevin M. Chin, Anja von Heydebreck, Luc Dirix, Hendrik Tobias Arkenau, Andres Forero-Torres, William Jeffery Edenfield, Petros Nikolinakos, Erika Hamilton, Martin Smakal, Robert Somer, István Takács, Guy Jerusalem, Jayne S. Gurtler, Ralph V. Boccia, Leisha A. Emens, Hans Juergen Grote, Marc E. Lippman
Publikováno v:
Breast Cancer Research and Treatment
Breast cancer research and treatment
Breast cancer research and treatment
Purpose Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this study was to assess the activity of avelumab, a PD-L1 inhibitor, in pa
Autor:
Karen Kelly, J. Thaddeus Beck, Manish R. Patel, Hans Juergen Grote, Jaspreet Grewal, Anja von Heydebreck, Michael S. Gordon, Vikram Chand, Christina M. Annunziata, Matthew H. Taylor, Erika Hamilton, Haeseong Park, Mary L. Disis, Jorge Chaves, James L. Gulley, Kathleen M. Moore, Alain C. Mita
Publikováno v:
JAMA oncology. 5(3)
Importance Current treatment options for progressive ovarian cancer provide limited benefit, particularly in patients whose disease has become resistant to platinum-based chemotherapy. Objective To assess the efficacy and safety of avelumab, an anti
Autor:
Janice M. Mehnert, Sebastian Bauer, Lucjan Wyrwicz, Kevin M. Chin, Anja von Heydebreck, Ulrich Keilholz, Donald Gravenor, Manish R. Patel, John Nemunaitis, Vijay Kasturi, Keun Wook Lee, Hugues Bourgeois, Matthew H. Taylor, James L. Gulley
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
191 Background: Avelumab is a human anti–PD-L1 IgG1 monoclonal antibody that is approved for the treatment of metastatic Merkel cell carcinoma (US and EU) and advanced urothelial carcinoma progressed on platinum therapy (US). Here, we report phase
Autor:
Matthew H. Taylor, Jean Pierre Delord, Samith T. Kochuparambil, John Nemunaitis, Anish Thomas, Afshin Dowlati, Kevin M. Chin, Anja von Heydebreck, Jaafar Bennouna, John D. Powderly, Claire F. Verschraegen, Raffit Hassan, Manish R. Patel, Franklin Chen, Ulka N. Vaishampayan, James L. Gulley, Hans Juergen Grote
Publikováno v:
JAMA oncology. 5(3)
Importance Patients with malignant mesothelioma whose disease has progressed after platinum and pemetrexed treatment have limited options. Anti–programmed cell death 1 (PD-1) antibodies have antitumor activity in this disease, but little is known a
Autor:
Paul Nghiem, Kevin M. Chin, Céleste Lebbé, Howard L. Kaufman, Anja von Heydebreck, Isaac Brownell, Shailender Bhatia, Sandra P. D'Angelo, Michele Milella, Jochen H. Lorch, Omid Hamid, Lisa Mahnke, Gerald P. Linette, Kent C. Shih, Jean Marie Cuillerot, Karl D. Lewis, Jeffery S. Russell, Patrick Terheyden
Publikováno v:
The Lancet Oncology. 17:1374-1385
Summary Background Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in patients with advanced disease. Current standard care uses various cytotoxic chemotherapy regimens, but responses are seldom durable. Tumour oncogenesis